Navigation Links
A first in front line immunity research
Date:7/21/2013

Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.

In a study published today in Nature Immunology, a team of researchers led by Professor Paul Hertzog, of the Monash Institute of Medical Research (MIMR) and Professor Jamie Rossjohn, of the School of Biomedical Sciences, have characterised for the first time how interferon beta (IFNβ) proteins bind to cells and activate an immune response.

Produced when viral and bacterial infections are detected, interferon proteins are vital to the body's defences. They activate immune cells, such as macrophages, can interfere with virus replication, and can boost cells' resilience to infection. They also enhance later immune responses to cancers and other stresses.

There are at least 20 subtypes of interferons that are produced at different stages of the immune response. They appear to have different functions, but these functions and their triggers are generally not well understood. The mapping of INFβ - cell interaction is a breakthrough in the field.

Professor Hertzog of MIMR's Centre for Innate Immunity and Infectious Diseases said interferon function was vital for developing and refining therapies for incurable diseases such as lupus and multiple sclerosis.

"Interferon therapy is useful in treating a number of diseases; however these treatments have dose-limiting side effects. Further, interferons appear to drive some autoimmune diseases, raising the prospect of interferon blockers as treatment," Professor Hertzog said.

"The more refined our understanding of interferon function, the more we can tailor treatments to optimise effectiveness - whether by boosting or blocking their actions."

Lead author on the paper, Dr Nicole de Weerd, also of the Centre for Innate Immunity and Infectious Diseases, said the research provided new pathways for rational drug design.

"We found that when IFNβ binds to a cell, it transmits an unusual signal that seems linked to some of the toxic side effects of interferon therapy, like sepsis. This provides a promising avenue to pursue more selective activation of interferon action," Dr de Weerd said.

Professor Rossjohn and Julian Vivian from the Department of Biochemistry and Molecular Biology collaborated closely on determining the IFNβ interactions at the molecular level.

"During this seven-year study, we have had great support from the Australian Synchrotron," Professor Rossjohn said.


'/>"/>

Contact: Emily Walker
emily.walker@monash.edu
61-399-034-844
Monash University
Source:Eurekalert

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... (PRWEB) , ... January 12, 2017 , ... ... to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months ... a new drug combination that has stabilized Rosendahl’s disease and increased both the ...
(Date:1/12/2017)... MERIDEN, Conn. , Jan. 12, 2017 /PRNewswire/ ... development company and maker of Flublok Influenza ... based Zika vaccine candidate had good safety results ... virus in preclinical studies. The product is expected ... next few months.  In addition, the Institute of ...
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock ... Global Forecast to 2022", published by MarketsandMarkets, the global market is estimated to ... 1,399.6 Million by 2022, at a CAGR of 6.96% from 2016. ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib ... a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients ...
Breaking Biology Technology: